Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

PURPOSE: Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and accelerated phase (AP; CML-AP) who are resistant to or intolerant of prior imatinib therapy. In this subanalysis of a phas...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Hughes, Timothy, Saglio, Giuseppe, Branford, Susan, Soverini, Simona, Kim, Dong-Wook, Müller, Martin C., Martinelli, Giovanni, Cortes, Jorge, Beppu, Lan, Gottardi, Enrico, Kim, Dongho, Erben, Philipp, Shou, Yaping, Haque, Ariful, Gallagher, Neil, Radich, Jerald, Hochhaus, Andreas
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2009
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979230/
https://ncbi.nlm.nih.gov/pubmed/19652056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.21.8230
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares